Business Context and Reporting Period
This Form 6-K filing by NewcelX Ltd. (formerly NLS Pharmaceutics Ltd.) covers the month of October 2025, specifically reporting on the completion of a merger transaction on October 30, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the structural completion of a corporate merger and a reverse stock split.
Material Changes
- Merger Completion: NLS Pharmaceutics Ltd. completed its merger with Kadimastem Ltd., creating an integrated biopharmaceutical company focused on cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.
- Corporate Name Change: The company officially changed its name to "NewcelX Ltd."
- Reverse Stock Split: A 1-for-10 reverse stock split was effected for common shares, preferred shares, and preferred participation certificates.
- Contingent Value Rights: Existing holders of NLS securities received contingent value rights regarding future net proceeds from the disposition of certain legacy assets (including Mazindol ER), excluding the DOXA platform.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the merger's successful closing and the strategic shift toward an integrated focus on neurodegenerative and metabolic disease therapies. The filing notes that the description of the Merger Agreement is subject to the full text of the agreement attached as Exhibit 99.1. No specific financial guidance or detailed risk factors are enumerated in this summary text.
Investor Verification Checklist
- Verify the terms of the Merger Agreement (Exhibit 99.1) for details on consideration and integration.
- Confirm the specific mechanics and valuation of the contingent value rights issued to legacy shareholders.
- Review the post-merger capital structure following the 1-for-10 reverse stock split.
- Assess the strategic roadmap for the combined entity's cell-based and small-molecule therapy pipeline.